Media coverage about Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) has been trending somewhat positive this week, Accern Sentiment reports. The research group ranks the sentiment of news coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Verona Pharma PLC American Depositary Share earned a coverage optimism score of 0.05 on Accern’s scale. Accern also assigned news stories about the company an impact score of 47.6163415681634 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
Verona Pharma PLC American Depositary Share (VRNA) opened at 12.1192 on Friday. The firm has a 50-day moving average of $12.12 and a 200-day moving average of $13.64. The company’s market capitalization is $134.09 million. Verona Pharma PLC American Depositary Share has a one year low of $11.03 and a one year high of $17.50.
Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) last issued its quarterly earnings results on Tuesday, August 8th. The company reported ($0.37) EPS for the quarter, missing analysts’ consensus estimates of ($0.28) by $0.09. On average, analysts anticipate that Verona Pharma PLC American Depositary Share will post ($2.23) earnings per share for the current year.
A number of equities analysts have commented on the stock. Zacks Investment Research downgraded shares of Verona Pharma PLC American Depositary Share from a “buy” rating to a “hold” rating in a report on Tuesday, August 8th. Wedbush assumed coverage on shares of Verona Pharma PLC American Depositary Share in a report on Monday, May 22nd. They issued an “outperform” rating and a $25.00 target price for the company. Stifel Nicolaus assumed coverage on shares of Verona Pharma PLC American Depositary Share in a report on Monday, May 22nd. They issued a “buy” rating and a $22.00 target price for the company. Jefferies Group LLC reiterated a “buy” rating and issued a $26.00 target price on shares of Verona Pharma PLC American Depositary Share in a report on Monday, May 22nd. Finally, SunTrust Banks, Inc. assumed coverage on shares of Verona Pharma PLC American Depositary Share in a report on Monday, May 22nd. They issued a “buy” rating and a $26.00 target price for the company. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus price target of $22.60.
COPYRIGHT VIOLATION WARNING: “Verona Pharma PLC American Depositary Share (VRNA) Earns Media Sentiment Rating of 0.05” was first reported by StockNewsTimes and is the property of of StockNewsTimes. If you are viewing this news story on another publication, it was stolen and reposted in violation of U.S. & international copyright & trademark law. The correct version of this news story can be accessed at https://stocknewstimes.com/2017/08/26/verona-pharma-plc-american-depositary-share-vrna-earns-media-sentiment-rating-of-0-05.html.
Verona Pharma PLC American Depositary Share Company Profile
Verona Pharma plc, a clinical stage biopharmaceutical company, researches, discovers, and develops therapeutic drugs to treat respiratory diseases primarily in the United Kingdom and North America. The companys lead product is RPL554, an inhaled dual inhibitor of the enzymes phosphodiesterase 3 and 4, which is in Phase IIa clinical trial that acts as a bronchodilator and an anti-inflammatory agent for the treatment of chronic obstructive pulmonary disease, cystic fibrosis, and asthma.
Receive News & Ratings for Verona Pharma PLC American Depositary Share Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verona Pharma PLC American Depositary Share and related companies with MarketBeat.com's FREE daily email newsletter.
